10-Q: Medinotec Q3 2025: Strong Profit Growth, Debt Reduction

Medinotec Inc. reported significant profit growth and substantial debt reduction in its Q3 2025 filing, driven by international sales, despite U.S. revenue decline and tariff concerns.

Summary

• Net income for the nine months ended November 30, 2025, increased by 26.6% to $863,761, up from $682,264 in the prior year.
• Consolidated revenue for the nine months ended November 30, 2025, grew by 41% to $7,907,325, compared to $5,588,445 in the prior year.
• Gross margin improved to 54% for the nine months ended November 30, 2025, from 44% in the prior year, primarily due to favorable product mix and operational factors.
• The company substantially repaid outstanding related party loans, reducing total liabilities from $2,538,144 to $1,352,691.
• Cash and cash equivalents increased to $2,856,926 as of November 30, 2025, from $2,769,686 as of February 28, 2025.
• Operating cash flow for the nine months ended November 30, 2025, was $1,027,439, up from $779,119 in the prior year.
• The "Outside the United States" segment revenue increased by 48% to $7,500,340 for the nine months, while the "Inside the United States" segment revenue decreased by 21% to $406,985.
• Operating expenses for the nine months ended November 30, 2025, increased by 135% to $2,914,822, driven by sales and marketing investments and compliance costs.
• A 30% U.S. tariff on South African imports, effective August 1, 2025, is expected to impact U.S. revenue and gross margins.
• The company received FDA 510(k) clearance for its OutFlo Aortic Dilatation Balloon Catheter on March 11, 2025, with a planned U.S. market launch in Q4 FY2026.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with significant revenue and net income growth, improved gross margins, and substantial debt reduction. Key product advancements and strategic uplisting plans are positive. However, significant customer concentration, increased operating expenses, and the newly imposed U.S. tariff introduce notable risks and challenges, along with the ineffective disclosure controls.

Positives

• Strong net income growth of 26.6% for the nine months ended November 30, 2025, reaching $863,761.
• Significant revenue increase of 41% for the nine months ended November 30, 2025, totaling $7,907,325.
• Gross margin improved by 10 percentage points to 54% for the nine months, indicating better product mix and operational efficiency.
• Substantial reduction in loans payable from $940,277 to $452, strengthening the balance sheet and reducing interest expenses.
• Positive operating cash flow of $1,027,439 for the nine months, demonstrating effective working capital management.
• FDA 510(k) clearance for the OutFlo Aortic Dilatation Balloon Catheter on March 11, 2025, expanding the product portfolio for the North American market.
• Management believes improving financial performance positions the company for a potential uplisting to the Nasdaq Capital Market.
• The "Outside the United States" segment showed robust revenue growth of 48% and a 31.8% increase in income from operations for the nine months.
• The company's strategy of leveraging less expensive, high-quality talent abroad is yielding positive results, enhancing cost efficiency.

Negatives

• Revenue in the "Inside the United States" segment decreased by 21% for the nine months ended November 30, 2025, to $406,985.
• The "Inside the United States" segment reported an operating loss of $(490,061) for the nine months, indicating it is in an active build-up phase with higher operating costs.
• Operating expenses for the nine months increased significantly by 135% to $2,914,822, primarily due to higher sales and marketing activities and compliance costs.
• The company derives 92% of its total revenue from a single customer, DISA Life Sciences, creating significant customer concentration risk.
• Disclosure controls and procedures were deemed not effective for the period ended November 30, 2025, with remediation expected by the end of fiscal year 2026.
• A newly imposed 30% U.S. tariff on South African imports, effective August 1, 2025, is expected to increase cost of goods sold for U.S.-bound shipments and potentially reduce gross margin by 1-2 percentage points.

Risks

• Financial Risks: Potential need for additional financing, exposure to interest rate changes, accounting rule shifts, and tax regulation updates.
• Operational Challenges: Dependence on product development, supply chain continuity, and competitive positioning; industry consolidation, pricing pressures, IT disruptions, and foreign exchange volatility.
• Customer and Market Exposure: Heavy reliance on a single customer, DISA Life Sciences (92% of revenue), increasing revenue concentration risk. Inadequate insurance coverage and internal control weaknesses.
• Management and Governance: Dependence on a small number of key personnel, many located outside the U.S.; concentrated voting power among founders; limited public-company experience heightens governance and compliance risks.
• Regulatory and Legal: Delays in obtaining regulatory approvals (e.g., FDA 510(k) processes), potential product liability, compliance with marketing and reimbursement rules, IP protection, and evolving environmental and data privacy laws.
• Geopolitical and Regional Risks: Political and economic instability in South Africa (load-shedding, exchange controls, FATF grey-listing) may impair operations. Broader geopolitical tensions and trade disputes affecting supply chains and market access.
• Newly Imposed U.S. Tariff: A 30% U.S. tariff on all goods imported from South Africa into the United States, effective August 1, 2025, could increase cost of goods sold by 30% on approximately 5% of revenue from the Domestic Sales segment, potentially reducing fiscal year gross margin by 1 to 2 percentage points if unmitigated.
• Market and Securities Risks: Shares trade on the OTCQX market and are considered penny stocks, which may limit liquidity. Future equity issuances could dilute existing shareholders, and share prices may fluctuate significantly due to external factors.
• Uplisting Risks: No assurance of meeting initial listing requirements for a national securities exchange (e.g., Nasdaq Capital Market) or maintaining such a listing. May require additional capital, which could be dilutive or on unfavorable terms.

Future Outlook

The company anticipates launching its OutFlo Aortic Dilatation Balloon Catheter to the U.S. market in Q4 of the 2026 financial year, following FDA clearance. Management believes its improving financial performance and operational progress position it to pursue an uplisting to a national securities exchange, such as the Nasdaq Capital Market, in the future. The company plans to undertake clinical write-ups in new territories to facilitate market entry and compliance, with anticipated costs not exceeding $50,000. It may also seek additional debt or equity financing or establish lines of credit to support potential acquisitions, strategic partnerships, capital expenditures, and R&D expansion. Remediation for identified deficiencies in disclosure controls and procedures is expected to be completed by the end of fiscal year 2026.

Management Comments

• "Management believes the Company's improving financial performance and operational progress position it to pursue an uplisting to a national securities exchange, such as the Nasdaq Capital Market, in the future."
• "Management anticipates that OutFlo will be launched to the U.S. Market in Q4 of the 2026 financial year, while the product is already in market in South Africa."
• "The company's strategy of leveraging less expensive, high-quality talent abroad is yielding positive results. This approach not only enhances our cost efficiency but also reinforces our commitment to maintaining a skilled workforce that is essential for driving our operations."
• "Management has decided to prioritize the repayment of loan accounts using spare cash flows generated by the business. This strategic decision aims to strengthen the Company's financial position and enhance financial stability."
• "We adopt an R&D-light approach. This strategy focuses on commercially viable projects, prioritizing investments that promise higher returns. Our R&D efforts are primarily centered on process improvement and manufacturing efficiencies rather than high-risk initiatives."

Industry Context

The global medical device market is projected to grow at a CAGR of 5.6% from 2024 to 2029, driven by rising healthcare expenditures, demographic shifts, and increasing demand in emerging markets. The U.S. medical device market is expected to grow at a CAGR of 4.3% from 2024 to 2029, fueled by advances in minimally invasive technologies and rising health spending, particularly with an aging population and increasing chronic respiratory conditions. Medinotec's expansion into these markets with products like the Trachealator and OutFlo aligns with these growth trends, especially in the minimally invasive and cardiovascular segments. However, the company faces challenges from geopolitical factors like the U.S. tariff on South African imports, which could impact its competitiveness and profitability in the U.S. market. The company's reliance on a single major distributor in South Africa also highlights a concentration risk that is not uncommon in specialized distribution models but warrants careful management in a growing market.

Comparison to Industry Standards

• The company's gross margin of 54% for the nine months ended November 30, 2025, is strong, especially considering the "thinner margins" from its distribution business. This suggests that its proprietary products (like Trachealator and OutFlo) are contributing significantly to profitability, which is a positive indicator compared to general medical device distributors.
• The company's "R&D-light approach" focusing on commercially viable projects and process improvements, rather than high-risk initiatives, contrasts with larger medical device companies that often invest heavily in fundamental research. This strategy aims for higher likelihood of success and cost efficiency, which can be a competitive advantage for a smaller company like Medinotec.
• The company's goal to uplist to a national securities exchange like Nasdaq Capital Market is a common aspiration for OTCQX-listed companies seeking greater liquidity and investor visibility, aligning with growth strategies seen across the industry for emerging medical technology firms.
• The 30% U.S. tariff on South African imports is a specific geopolitical challenge that could put Medinotec at a disadvantage compared to competitors sourcing from other regions or manufacturing within the U.S. This external factor is not an industry standard but a significant market condition impacting the company's U.S. segment.
• The high customer concentration (92% from DISA Life Sciences) is a notable deviation from best practices for revenue diversification, which typically aims to limit reliance on any single customer to mitigate business risk.

Corporate Governance

Legal Proceedings

• The company is not a party to any material pending legal proceedings.
• No awareness of any pending legal proceeding to which officers, directors, or 5% beneficial holders are adverse to the company or have a material adverse interest.

Related Party Transactions

• Loans Payable: Unsecured loan of $160 from Minoan Medical Proprietary Limited (prior parent entity of DISA Medinotec, controlled by CEO Dr. Gregory Vizirgianakis). This loan was substantially repaid during the nine months ended November 30, 2025.
• Loans Payable: Unsecured, interest-free loan of $292 from Minoan Capital Proprietary Limited (property investment company controlled by CEO Dr. Gregory Vizirgianakis), with no fixed terms of repayment.
• Lease Agreement: DISA Medinotec Proprietary Limited leases commercial buildings from Minoan Capital (controlled by CEO Dr. Gregory Vizirgianakis). Lease payments for the three months ended November 30, 2025, were $8,505, and for the nine months, $24,729. Management believes terms are consistent with market rates.
• Executive Management Costs: Allocation of executive management costs to the company from its distributor (which employs certain executives providing services to the company) based on time spent on company-related activities, resulting in a recurring monthly charge of approximately $50,000 since March 2025.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong financial performance, debt reduction, and uplisting aspirations. However, dilution risk from future capital raises and stock price volatility due to market risks and geopolitical factors.
• Employees: Continued employment and potential growth opportunities, especially with expansion plans. The strategy of leveraging less expensive talent abroad could impact hiring in the U.S.
• Customers: Continued access to medical devices, including new products like OutFlo. U.S. customers may face price increases or reduced competitiveness due to tariffs on South African imports.
• Suppliers: Stable relationships, with the company effectively managing payables.
• Creditors: Improved creditworthiness due to significant debt repayment and stronger financial position.
• Regulatory Authorities: Ongoing compliance efforts, including addressing disclosure control deficiencies and seeking FDA approvals.

Next Steps

• Launch OutFlo Aortic Dilatation Balloon Catheter to the U.S. market in Q4 of the 2026 financial year.
• Actively assess the potential impact of the 30% U.S. tariff on South African imports and evaluate contingency strategies, including sourcing alternatives, pricing adjustments, and geographic diversification of revenue.
• Continue pursuing opportunities to enhance sales and distribution operations in the U.S.
• Pursue an uplisting to a national securities exchange, such as the Nasdaq Capital Market.
• Undertake clinical write-ups in new territories to facilitate market entry and compliance with local regulations.
• Complete remediation for deficiencies in disclosure controls and procedures by the end of fiscal year 2026.
• Consider seeking additional debt or equity financing or establishing lines of credit to support potential acquisitions, strategic partnerships, capital expenditures, and R&D expansion.
• Applications for quality accreditations (e.g., TGF, JIS & CFDA) for Trachealator will be considered upon achieving a critical mass of sales in the USA & Europe.
• Continue progress on FDA 510(k) clearance for Cape Cross PTCA Catheter and Cape Cross NC Catheter.
• Continue progress on CE certification under the MDR for Cape Cross PTCA Catheter and Cape Cross NC Catheter.
• Continue examination of the Technical File for Micro CTO Catheter by Notified Body.

Key Dates

Recommendation

The company demonstrates strong financial health with significant revenue and net income growth, coupled with a substantial reduction in debt, which materially strengthens its balance sheet and reduces financial risk. The improved gross margins indicate operational efficiency. Strategic product launches, like the OutFlo Aortic Dilatation Balloon Catheter, and the ambition to uplist to Nasdaq, suggest strong future growth potential and increased market visibility. While customer concentration and the U.S. tariff pose risks, the company is actively pursuing mitigation strategies and market diversification. The overall trajectory of profitability and strategic initiatives makes it an attractive investment for long-term growth, despite the noted internal control deficiencies which are being addressed.

Keywords

Medical Devices, SEC Filing, 10-Q, Medinotec, MDNC, Trachealator, OutFlo Catheter, FDA Approval, South Africa, US Market, Financial Results, Quarterly Report, Medical Technology, Corporate Governance, Risk Factors, Nasdaq Uplisting, Tariff Impact, Customer Concentration, Medical Device Distribution, Cardiology, Respiratory Devices